Solid Tumor Protocols / Clinical Studies

For information on these and other studies, referring physicians may e-mail protocolinfo@stjude.org or call toll free physician referral line, 1-888-226-4343. If you are not a physician, please e-mail info@stjude.org for information on St. Jude studies.

 

Therapeutic Trial for Newly Diagnosed Patients with Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

For: Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

 
 

International Pediatric Adrenocortical Tumor Registry Data Collection

For: adrenocortical carcinoma

 
 

An Open- Label, Dose Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescent Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations.

For: Refractory or refractory solid tumor

 
 

Neuroblastoma Protocol 2012: Therapy for Children with Advanced Stage High-Risk Neuroblastoma

For: Neuroblastoma

 
 

A Phase I Trial of RAD001 (Everolimus) and AVASTIN (Bevacizumab) in Children with Recurrent Solid Tumors

For: Refractory/relapsed solid tumor or brain tumor

 
 

A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children with Relapsed or Refractory Solid Tumors or Lymphomas

For: Relapsed or refractory solid tumors or lymphomas

 
 

Risk Adapted Focal Proton Beam Radiation and/or Surgery in Participants with Low and Intermediate Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

For: Rhabdomyosarcoma (Low-risk and intermediate-risk)

 
 

Phase II Study of Alisertib As A Single Agent in Recurrent or Progressive Central Nervous System Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT

For: Recurrent, progressive, or newly diagnosed Atypical Teratoid Rhabdoid Brain Tumors (ATRT)
Solid Tumor : Progressive extra-CNS Malignant Rhabdoid Solid Tumors (MRT)

 
 

A Phase I trial of the humanized anti-GD2 antibody (hu14.18K322A) in children and adolescents with neuroblastoma, osteosarcoma and melanoma

For: Neuroblastoma, osteosarcoma and melanoma

 
 

Protocol for the Study and Treatment of Participants with Intraocular Retinoblastoma

For: Retinoblastoma

 

Non St. Jude Protocols

 

A Phase I Study of Crizotinib (IND#105573) In Combination with Conventional Chemotherapy For Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

For: Relapsed or refractory solid tumors or anaplastic large cell lymphoma

 
 

A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors (ADVL1312)

For: Relapsed or refractory solid tumors

 
 

A Phase I/II Study of PF-02341066, An Oral Small Molecule Inhibitor Of Anaplastic Lymphoma Kinase (ALK) And C-Met, In Children With Relapsed/Refractory Solid Tumors And Anaplastic Large Cell Lymphoma

For: Relapses/refractory solid tumors and anaplastic large cell lymphoma

 
 

Phase I/II a, 2-Part, Multi-Cancer, Single-Arm, Open-Label Study to determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to < 18 Years with Advance BRAF V600-Mutation Positive Solid Tumors

For: Solid tumors, giomas, hystiosytosis

 
 

A Phase I, Open-Label, Dose Escalation Study of LDK378 in Pediatric Patients with Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

For: Refractory or progressive malignancies

 
 

A Phase 2 Study of Ipilimumab in Children and adolescents (12 to < 18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma

For: Previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma

 
 

An Open-label, Multicenter, Single-arm, Phase I Dose-escalation with Efficacy Tail Extension study of R05185426 in Pediatric Patients with Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600

For: melanoma

 
 

Utilizing Response and Biology-Based Risk Factors to guide Therapy in Patients with Non-High Risk Neuroblastoma Site CTEP ID= TN024

For: Neuroblastoma

 
 

Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy

For: Nasopharyngeal carcinoma

 
 

Treatment for Patients with Bilateral, Multicentric, or Bilaterally- Predisposed Unilateral Wilms Tumor

For: Wilms tumor

 
 

A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma

For: Extra-occular retinoblastoma

 
 

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue (PAZNTIS): A Phase II/III Randomized Trial of Pre-Operative Chemo radiation or Preoperative Radiation Plus or Minus Pazopanib

For: Non-rhabdomyosarcoma soft tissue

 
 

A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung

For: recurrent osteosarcoma

 
 

A Phase II Study of Hypofractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites

For: Metastatic sarcomas